{"id":1141,"date":"2020-03-17T14:05:09","date_gmt":"2020-03-17T14:05:09","guid":{"rendered":"https:\/\/www.almacgroup.com\/diagnostics\/?post_type=diagnostic_resource&#038;p=1141"},"modified":"2020-03-17T14:05:12","modified_gmt":"2020-03-17T14:05:12","slug":"association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance","status":"publish","type":"diagnostic_resource","link":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/","title":{"rendered":"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)"},"content":{"rendered":"\n<p>Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further validate ColDx using formalin-fixed, paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581. Our conclusion is that ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, including MMR deficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis.<\/p>\n","protected":false},"featured_media":0,"template":"","diagnostics_type":[477],"class_list":["post-1141","diagnostic_resource","type-diagnostic_resource","status-publish","hentry","diagnostics_type-diagnostics-publications"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3.1 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) - Diagnostic Services<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)\" \/>\n<meta property=\"og:description\" content=\"Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Diagnostic Services\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-17T14:05:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"100\" \/>\n\t<meta property=\"og:image:height\" content=\"52\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/\",\"name\":\"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) - Diagnostic Services\",\"isPartOf\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\"},\"datePublished\":\"2020-03-17T14:05:09+00:00\",\"dateModified\":\"2020-03-17T14:05:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.almacgroup.com\/diagnostics\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"name\":\"Diagnostic Services\",\"description\":\"Just another Almac Core Sites site\",\"publisher\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\",\"name\":\"Almac Group Ltd\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"width\":643,\"height\":296,\"caption\":\"Almac Group Ltd\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) - Diagnostic Services","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/","og_locale":"en_GB","og_type":"article","og_title":"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)","og_description":"Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further [&hellip;]","og_url":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/","og_site_name":"Diagnostic Services","article_modified_time":"2020-03-17T14:05:12+00:00","og_image":[{"width":100,"height":52,"url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/","name":"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) - Diagnostic Services","isPartOf":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website"},"datePublished":"2020-03-17T14:05:09+00:00","dateModified":"2020-03-17T14:05:12+00:00","breadcrumb":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.almacgroup.com\/diagnostics\/diagnostic-resource\/association-between-results-of-a-gene-expression-signature-assay-and-recurrence-free-interval-in-patients-with-stage-ii-colon-cancer-in-cancer-and-leukemia-group-b-9581-alliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.almacgroup.com\/diagnostics\/"},{"@type":"ListItem","position":2,"name":"Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)"}]},{"@type":"WebSite","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website","url":"https:\/\/www.almacgroup.com\/diagnostics\/","name":"Diagnostic Services","description":"Just another Almac Core Sites site","publisher":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization","name":"Almac Group Ltd","url":"https:\/\/www.almacgroup.com\/diagnostics\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","contentUrl":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","width":643,"height":296,"caption":"Almac Group Ltd"},"image":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostic_resource\/1141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostic_resource"}],"about":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/types\/diagnostic_resource"}],"wp:attachment":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/media?parent=1141"}],"wp:term":[{"taxonomy":"diagnostics_type","embeddable":true,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/diagnostics_type?post=1141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}